Fate Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $1,860 | $3,074 | $6,772 | $1,925 |
Gross Profit | 1,860 | 3,074 | -27,832 | -2,896 |
EBITDA | -42,198 | -52,377 | -40,362 | -46,247 |
EBIT | -47,011 | -45,083 | -51,068 | |
Net Income | -52,153 | -47,678 | -38,427 | -48,004 |
Net Change In Cash | 1,860 | 3,074 | 6,772 | 1,925 |
Free Cash Flow | -27,897 | -29,914 | -32,357 | -33,436 |
Cash | 36,056 | 37,909 | 36,917 | 121,322 |
Basic Shares | 115,727 | 117,769 | 117,468 | 101,104 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $13,631 | $63,533 | $96,300 | $55,846 |
Gross Profit | 13,631 | -98,163 | 96,300 | 49,996 |
EBITDA | -176,577 | -172,229 | -294,628 | -211,144 |
EBIT | -195,539 | -190,511 | -308,386 | -216,994 |
Net Income | -186,262 | -160,928 | -255,056 | -206,301 |
Net Change In Cash | 13,631 | 63,533 | 96,300 | 55,846 |
Cost of Revenue | -33,764 | |||
Free Cash Flow | -123,604 | -138,416 | -283,774 | -213,574 |
Cash | 36,056 | 41,870 | 61,333 | 133,583 |
Basic Shares | 113,685 | 98,411 | 96,826 | 94,747 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.44 |
2024-09-30 | -$0.40 |
2024-06-30 | -$0.33 |
2024-03-31 | -$0.47 |
